By Jody Osborne, Optionetics.com – Biotech stocks fell sharply after ImClone (IMCL) fell 15.9 percent. The stock stumbled after the FDA didn’t accept the company’s filing for Erbitux, an experimental cancer treatment drug. The Biotechnology Index (^BTK) fell 3.61% on the day. Software shares fell al
Read More - Register for Free Membership
SQL Server, Azure SQL Database, Amazon RDS & AWS, Oracle and IBM Help